High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction

International Journal of Impotence Research

Volumn 14, Issue 6, 2002, Pages 533-538

  McMahon, C G ^a  

^a Australian Centre for Sexual Health   (Australia)

Author keywords

Cavernosal veno occlusive dysfunction; Erectile dysfunction; Intracavernous injections; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPILEPTIC AURA; ERECTILE DYSFUNCTION; HEADACHE; HOT FLUSH; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; PENIS ERECTION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSTATECTOMY; SALVAGE THERAPY; SEXUAL INTERCOURSE; TREATMENT OUTCOME; VEIN OCCLUSION; VERTIGO; VISUAL IMPAIRMENT;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036933689     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900936     Document Type: Article

References (27)

1. NIH Consensus Conference. Impotence, NIH Consensus Development Panel on Impotence. JAMA 1983; 270: 83-90.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537-544.
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
4. Bortolotti A, Parazzini F, Colli E, Landoni M. The epidemiology of erectile dysfunction and its risk factors. Int J Androl 1997; 20: 323-334.
5. Jonler M, Moon T, Brannan W, Stone NN, Heisey D, Bruskewitz RC. The effect of age, ethnicity and geographical location on impotence and quality of life. Br J Urol 1995; 75: 651-655.
6. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. New Engl J Med 1998; 338: 1397-1404
7. Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
8. Dinsmore WW, Hodges M, Hargreaves C, Osterloh JH, Smith MD, Rosen RC. Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology 1999; 53: 800-805.
9. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722-725.
10. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073-1077.
11. McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as a treatment for erectile dysfunction. J Urol 2000; 164: 1192-1196.
12. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997; 157: 2135-2138.
13. Steers WD et al. Sildenafil (Viagra) is effective in the treatment of severe erectile dysfunction. In: Proceedings of the Second Meeting of the European Society for Impotence Research, Madrid. Int J Impot Res 1998; 10: S49.
14. McMahon CG, Samali R, Johnston HM. Treatment of intracorporal injection non-responders with sildenafil alone or in combination with polyagent intracorporal injections. J Urol 1999; 162(6): 1992-1997.
15. TM) is not affected by etiology of erectile dysfunction. Int J Impot Res 1998; 10: S32.
16. TM) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra) Urology 2000; 55(4): 477-480.
17. Joint Clinical Review for NDA-20-985 - Sildenafil for male impotence. Study 148-106. 22 January, 1999, pp 126-130.
18. Lowentritt BH et al. Sildenafil citrate after radical retropubic prostatectomy. J Urol 1999; 162(5): 1614-1617.
19. Hong EK, Lepor H, McCullough AR. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 1999; 11(Suppl 1): S15-S22.
20. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74.
21. Porst HJ. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience. Urol 1996; 155: 802-815.
22. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
23. Anderson M, Nicholson B, Louie E, Mulhall JP. An analysis of vasculogenic erectile dysfunction as a predictor of occult cardiac disease: J Urol 1998; 159: 30.
24. Matsuzawa I, Kondo Y, Horiuchi K, Akimoto M, Yokohama H. Cardiac evaluation using treadmill test for ED patients before treatment with sildenafil citrate. Int J Impot Res 2001; 13(Suppl 1): S72.
25. Kawanishi Y et al. Ischaemic heart disease in patients with erectile dysfunction. Int J Impot Res 2001; 13(Suppl 1): S76.
26. O'Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract 2001; 55: 219-220.
27. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33: 273-282.